Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ward assessment of SmartIdeas Project: bringing source isolation to the patient.
Moore G, Ali S, FitzGerald G, Muzslay M, Atkinson S, Smith S, Cryer P, Gush C; SmartIdeas Research Student Group; Wilson AP. Moore G, et al. Among authors: atkinson s. J Hosp Infect. 2010 Oct;76(2):103-7. doi: 10.1016/j.jhin.2010.04.017. Epub 2010 Jun 18. J Hosp Infect. 2010. PMID: 20561713
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, Oxley J, Robinson M, Staffurth J, Walsh E, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Paul A, Powell P, Prescott S, Rosario DJ, Rowe E, Neal DE; ProtecT Study Group. Hamdy FC, et al. N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14. N Engl J Med. 2016. PMID: 27626136 Free article. Clinical Trial.
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
Neal DE, Metcalfe C, Donovan JL, Lane JA, Davis M, Young GJ, Dutton SJ, Walsh EI, Martin RM, Peters TJ, Turner EL, Mason M, Bryant R, Bollina P, Catto J, Doherty A, Gillatt D, Gnanapragasam V, Holding P, Hughes O, Kockelbergh R, Kynaston H, Oxley J, Paul A, Paez E, Rosario DJ, Rowe E, Staffurth J, Altman DG, Hamdy FC; ProtecT Study Group. Neal DE, et al. Eur Urol. 2020 Mar;77(3):320-330. doi: 10.1016/j.eururo.2019.10.030. Epub 2019 Nov 24. Eur Urol. 2020. PMID: 31771797 Free article. Clinical Trial.
Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer -5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life.
Jiang XY, Atkinson S, Pearson R, Leaning D, Cumming S, Burns A, Azzabi A, Frew J, McMenemin R, Pedley ID. Jiang XY, et al. Among authors: atkinson s. Clin Oncol (R Coll Radiol). 2020 Oct;32(10):e177-e187. doi: 10.1016/j.clon.2020.05.002. Epub 2020 May 21. Clin Oncol (R Coll Radiol). 2020. PMID: 32448724 Clinical Trial.
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).
Lane JA, Donovan JL, Young GJ, Davis M, Walsh EI, Avery KNL, Blazeby JM, Mason MD, Martin RM, Peters TJ, Turner EL, Wade J, Bollina P, Catto JWF, Doherty A, Gillatt D, Gnanapragasam V, Hughes O, Kockelbergh R, Kynaston H, Oxley J, Paul A, Paez E, Rosario DJ, Rowe E, Staffurth J, Neal DE, Hamdy FC, Metcalfe C; Prostate Testing for Cancer and Treatment (ProtecT) Study Group. Lane JA, et al. BJU Int. 2022 Sep;130(3):370-380. doi: 10.1111/bju.15739. Epub 2022 May 3. BJU Int. 2022. PMID: 35373443 Free PMC article. Clinical Trial.
The administration of blood components: a British Society for Haematology Guideline.
Robinson S, Harris A, Atkinson S, Atterbury C, Bolton-Maggs P, Elliott C, Hawkins T, Hazra E, Howell C, New H, Shackleton T, Shreeve K, Taylor C. Robinson S, et al. Among authors: atkinson s. Transfus Med. 2018 Feb;28(1):3-21. doi: 10.1111/tme.12481. Epub 2017 Nov 6. Transfus Med. 2018. PMID: 29110357 No abstract available.
Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition.
Fogal V, Michopoulos F, Jarnuczak AF, Hamza GM, Harlfinger S, Davey P, Hulme H, Atkinson SJ, Gabrowski P, Cheung T, Grondine M, Hoover C, Rose J, Bray C, Foster AJ, Askin S, Majumder MM, Fitzpatrick P, Miele E, Macdonald R, Keun HC, Coen M. Fogal V, et al. Among authors: atkinson sj. Arch Toxicol. 2024 May 17. doi: 10.1007/s00204-024-03771-w. Online ahead of print. Arch Toxicol. 2024. PMID: 38755480
A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry.
Schwantes-An TH, Whitfield JB, Aithal GP, Atkinson SR, Bataller R, Botwin G, Chalasani NP, Cordell HJ, Daly AK, Darlay R, Day CP, Eyer F, Foroud T, Gawrieh S, Gleeson D, Goldman D, Haber PS, Jacquet JM, Lammert CS, Liang T, Liangpunsakul S, Masson S, Mathurin P, Moirand R, McQuillin A, Moreno C, Morgan MY, Mueller S, Müllhaupt B, Nagy LE, Nahon P, Nalpas B, Naveau S, Perney P, Pirmohamed M, Seitz HK, Soyka M, Stickel F, Thompson A, Thursz MR, Trépo E, Morgan TR, Seth D; GenomALC Consortium. Schwantes-An TH, et al. Among authors: atkinson sr. Hepatol Commun. 2024 May 10;8(6):e0431. doi: 10.1097/HC9.0000000000000431. eCollection 2024 Jun 1. Hepatol Commun. 2024. PMID: 38727677 Free PMC article.
1,296 results